Press Release

VetrixBio today highlighted the strength of its leadership and advisory team, bringing together experience across biotechnology, veterinary medicine, and drug development. The company is supported by a group of advisors with…

VetrixBio today announced preliminary safety and efficacy data from its first in vivo study of VTX-304, the company’s lead program for osteoarthritis in dogs. The study, conducted in a natural…

VetrixBio today provided an update on its oncology program, highlighting continued progress in the development of VTX-301/302, a localized immunotherapy combination for the treatment of cancer in companion animals. The program…

VetrixBio today highlighted its development strategy in osteoarthritis, centered on a dual-target biologic approach designed to address both pain and the underlying progression of disease. Osteoarthritis is one of the…

Graham Lumsden and Peter Hanson today announced the formation of VetrixBio, a biotechnology company focused on developing novel therapies for companion animals. VetrixBio was founded on a simple premise: pets…